C
Catherine Rowan
Researcher at University College Dublin
Publications - 19
Citations - 238
Catherine Rowan is an academic researcher from University College Dublin. The author has contributed to research in topics: Inflammatory bowel disease & Medicine. The author has an hindex of 6, co-authored 14 publications receiving 154 citations.
Papers
More filters
Journal ArticleDOI
Acceptance and Commitment Therapy Reduces Psychological Stress in Patients With Inflammatory Bowel Diseases
Brona Wynne,Louise McHugh,Wei Gao,Denise Keegan,K. Byrne,Catherine Rowan,K Hartery,Clemens Kirschbaum,Glen A. Doherty,Garret Cullen,Barbara Dooley,Hugh Mulcahy +11 more
TL;DR: In a randomized controlled trial of patients with IBD, an 8-week ACT therapy course improved stress and other indices of psychological health.
Journal ArticleDOI
Ustekinumab Drug Levels in Maternal and Cord Blood in a Woman With Crohn’s Disease Treated Until 33 Weeks of Gestation
Catherine Rowan,Garret Cullen,Hugh Mulcahy,Denise Keegan,K. Byrne,Deirdre J. Murphy,Juliette Sheridan,Glen A. Doherty +7 more
TL;DR: A 35-year old woman with ileocolonic, perianal, and vulval Crohn's disease was treated with subcutaneous ustekinuamb [USK] throughout pregnancy, and a healthy baby boy was delivered by caesarean section at 37 weeks.
Journal ArticleDOI
DUBLIN [Degree of Ulcerative colitis Burden of Luminal Inflammation] Score, a Simple Method to Quantify Inflammatory Burden in Ulcerative Colitis.
Catherine Rowan,Garret Cullen,Hugh Mulcahy,Juliette Sheridan,Alan C. Moss,Elizabeth J. Ryan,Glen A. Doherty +6 more
TL;DR: The DUBLIN score is a simple measure of inflammatory burden which correlates with objective inflammatory markers and is associated with clinical outcomes such treatment failure, and has the potential to assist in personalising therapy for patients with UC.
Journal ArticleDOI
Subcutaneous rather than intravenous ustekinumab induction is associated with comparable circulating drug levels and early clinical response: a pilot study
Catherine Rowan,Denise Keegan,K. Byrne,Garret Cullen,Hugh Mulcahy,Juliette Sheridan,Elizabeth J. Ryan,A C de Vries,G R D’Haens,Glen A. Doherty +9 more
TL;DR: Ustekinumab (USK) is licenced for intravenous induction and subcutaneous (S/C) maintenance in Crohn's disease.
Journal ArticleDOI
Severe Symptomatic Primary CMV Infection in Inflammatory Bowel Disease Patients with Low Population Seroprevalence
Catherine Rowan,Ciaran Judge,Mary Cannon,Garret Cullen,Hugh Mulcahy,Elizabeth J. Ryan,Cillian De Gascun,Glen A. Doherty +7 more
TL;DR: In areas where adult CMV seroprevalence is low, evidence of CMV should be sought in IBD patients presenting with any febrile systemic illness, particularly those receiving immunosuppression.